Abstract
An epidermal growth factor receptor (EGFR) has been reported to be associated with a poor clinical outcome in breast cancer, while its prognostic value remains controversial. Immunohistochemical staining for EGFR was performed on frozen sections of primary breast cancer from 1029 patients with a mean follow-up duration of 46 months. EGFR was positive in 277 (26.9%) of 1029 cases, which inversely correlated with the estrogen receptor (ER) status. A univariated analysis indicated that EGFR had a significant prognostic value in both the disease free survival (DFS) and the overall survival (OS), while the same effect was also found in node negative as well as node positive breast cancer. A multivariate analysis indicated that EGFR was an independently significant prognostic factor for DFS (p = 0.0174) and OS (p = 0.0105) in all patients, but that EGFR demonstrated a prognostic significance only for DFS (p =0.0241) in node negative and only for OS (p = 0.0333) in node positive breast cancer. When all patients were stratified for EGFR and ER, a multivariate analysis indicated that the combination of EGFR(+)/ER(−) was an independently significant factor for both DFS and OS in node negative as well as node positive breast cancer. In conclusion, the prognostic value of EGFR was demonstrated by a multivariate analysis in a large series of breast cancer patients, but the value of EGFR was somewhat insufficient to achieve statistical significance for both DFS and OS in the subgroups divided by nodal status. On the other hand, the prognostic value of combination of EGFR and ER was sufficient to achieve statistical significance based on a multivariate analysis for both DFS and OS in the subgroups of node negative as well as node positive breast cancer patients.
Similar content being viewed by others
References
Normanno H, Ciardiell F, Brandt R, Salmon DS: Epidermal growth factor-related peptides in the pathogenisis of human breast cancer. Breast Cancer Res Treat 29: 11–27, 1994
Helden CH, Westermak B: Growth factors: mechanisms of action and relation to oncogenes. Cell 37: 9–15, 1984
Sainsbury JR, Farndorn JR, Needham GK, Malcolm AJ, Harris AL: Epidermal-growth-factor receptor status as a predictor of early recurrence of and death from breast cancer. Lancet I: 1398–1402, 1987
Costa S, Stamm H, Almendral A, Ludwig H, Wyss R, Fabbro D, Ernst A, Takahashi A, Eppenberger U: Predictive value of EGF receptor in breast cancer. Lancet 2: 1258, 1988
Foekens JA, Portengen H, van Putten WLJ, Trapman AMAC, Reubi JC, Alexieva-Figusch J, Klijn JGM: Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49: 7002–7009, 1989
Nicholson S, Richard J, Sainsbury C, Halcrow P, Kelly P, Angus B, Wright C, Henry J, Farndon JR, Harris AL: Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node egative group. Br J Cancer 63: 146–150, 1991
Koenders PG, Beex LVAM, Kienhuis CBM, Kloppenborg PWC, Benraad ThJ: Epidermal growth factor recptor and prognosis in human breast cancer: a prospective study. Breast Cancer Res Treat 25: 21–27, 1993
Klijn JGM, Look MP, Portengen H, Alexieva-Figusch J, van Putten WLJ, Foekens JA: The prognostic value of epidermal grwoth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res Treat 29:73–83, 1994
Seshadri R, Mcleay WRB, Horsefall DJ, McCaul K: Prospective study of the prognostic significance of epidermal growth factor receptor in primary breast cancer. Int J Cancer 69: 23–27, 1996
Torregrosa D, Bolufer P, Lluch A, Lopex JA, Barragan E, Ruiz A, Guillem V, Munarriz B, Conde JG: Prognostic significance of c-erb-B2/neu amplification an depidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status. Clinica Chimica Acta 262: 99–119, 1997
Fox SB, Smith K, Hollyer J, Greenal M, Hastrich D, Harris Al: The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res Treat 29: 41–49, 1994
Klijn JGM, Berns PMJJ, Schmitz PIM, Foekens JA: The clinical significane of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients. Endocrine Rev 13: 156–170, 1992
Klijn JGM, Berns PHJJ, Schmitz PIM, Foekens JA: Epidermal growth factor receptor (EGFR-R) in clinical breast cancer: update 1993. Endocrine Rev 1: 171–174, 1993
Myoken Y, Okamoto T, Osaki T, Yabumoto M, Sato GH, Takada K, Sato JT: An alternative method for the isolation of NS-1 hybridomas using cholesterol auxotrophy of NS-1 mouse myeloma cells. In Vitro Cell Dev Biol 25: 477–480, 1989
Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, Altman DG: c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes.Br J Cancer 63: 434–438, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tsutsui, S., Ohno, S., Murakami, S. et al. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 71, 67–75 (2002). https://doi.org/10.1023/A:1013397232011
Issue Date:
DOI: https://doi.org/10.1023/A:1013397232011